---
schema_version: "secwatch.filing_event.v1"
accession: "0001837607-26-000043"
form_type: "8-K"
ticker: "AEON"
cik: "0001837607"
company_name: "AEON Biopharma, Inc."
filed_at: "2026-05-14T20:10:16+00:00"
generated_at: "2026-05-14T20:56:31.964930+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.2
confidence: "low"
source: SEC EDGAR
---

# AEON Biopharma posts corporate presentation targeting $3.5B neurotoxin market

## Summary
- Corporate presentation made available on IR website, dated May 2026.
- Presentation states AEON aims to disrupt a $3.5B neurotoxin market dominated by a single brand for over 30 years.
- No specific financial results, clinical updates, or guidance changes disclosed in the filing.

## SEC filing metadata
- accession: 0001837607-26-000043
- form_type: 8-K
- ticker: AEON
- cik: 0001837607
- company_name: AEON Biopharma, Inc.
- filed_at: 2026-05-14T20:10:16+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.2
- confidence: low
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1837607/000183760726000043/0001837607-26-000043-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1837607/000183760726000043/aeon-20260514x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001837607-26-000043
- JSON: https://secwatch.observer/filing/0001837607-26-000043.json
- Plain text: https://secwatch.observer/filing/0001837607-26-000043.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.